

EMA/307483/2024

European Medicines Agency decision P/0273/2024

of 14 August 2024

on the acceptance of a modification of an agreed paediatric investigation plan and on the granting of a waiver for COVID-19 vaccine (ChAdOx1-S [recombinant]), (EMA-002862-PIP01-20-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0273/2024

of 14 August 2024

on the acceptance of a modification of an agreed paediatric investigation plan and on the granting of a waiver for COVID-19 vaccine (ChAdOx1-S [recombinant]), (EMA-002862-PIP01-20-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0003/2021 issued on 5 January 2021, the decision P/0266/2021 issued on 7 July 2021, and the decision P/0559/2021 issued on 27 December 2021,

Having regard to the application submitted by AstraZeneca AB on 12 March 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and proposing a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 June 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for COVID-19 vaccine (ChAdOx1-S [recombinant]), suspension for injection, intramuscular use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A waiver for COVID-19 vaccine (ChAdOx1-S [recombinant]), suspension for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to AstraZeneca AB, Södertälje, SE-151 85 – Södertälje, Sweden.

EMA/PDCO/142429/2024
Amsterdam, 28 June 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan and on the granting of a product-specific waiver

EMA-002862-PIP01-20-M04

Scope of the application

Active substance(s):

COVID-19 vaccine (ChAdOx1-S [recombinant])

Invented name and authorisation status:

See Annex II

Condition(s):

Prevention of coronavirus disease 2019 (COVID-19)

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

AstraZeneca AB

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AstraZeneca AB submitted to the European Medicines Agency on 12 March 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0003/2021 issued on 5 January 2021, the decision P/0266/2021 issued on 7 July 2021, and the decision P/0559/2021 issued on 27 December 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and proposed a waiver for all subsets of the paediatric population.

The procedure started on 29 April 2024.

Scope of the modification

Measures and timelines of the Paediatric Investigation Plan have been modified and amended to a full product-specific waiver.

Opinion

The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion;
- to grant a product-specific waiver for all subsets of the paediatric population concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Prevention of coronavirus disease 2019 (COVID-19)

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- suspension for injection, intramuscular use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing vaccines.

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.